(Q54462541)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23273080%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

title

Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23273080%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23273080%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

2

Pierre Karakiewicz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23273080%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Alfonsus J M van den Eertwegh

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23273080%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Sevil Bavbek

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23273080%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Sergio Bracarda

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23273080%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Amit Bahl

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23273080%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Yen-chuan Ou

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23273080%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Dennis Kim

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23273080%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Ashok Panneerselvam

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23273080%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Oezlem Anak

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23273080%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Viktor Grünwald

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23273080%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

language of work or name

English

0 references

publication date

1 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23273080%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23273080%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

81

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23273080%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23273080%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

143-149

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23273080%20AND%20SRC:MED&resulttype=core&format=json

mTOR inhibitors in advanced renal cell carcinoma

21 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.09.019

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.09.019

EAU guidelines on renal cell carcinoma: the 2010 update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.09.019

EORTC-GU group expert opinion on metastatic renal cell cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.09.019

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.09.019

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.09.019

Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.09.019

An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.09.019

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.09.019

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.09.019

A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.09.019

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.09.019

Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.09.019

Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.09.019